Summary
The plasma and urinary levels of triamterene and two metabolites were measured using a specific method of analysis. Urinary excretion was completed after 48 h, which permitted a rough estimate of its half-life as longer than two hours. The areas under the curve were 672.5±160.3 and 1.311.3±399.1 µg/ml × h after the triameterene 150 mg and 300 mg p.o., respectively and correspondingly 4.2±1.4% and 3.7±0.6% of the dose were excreted as unchanged drug. The principal metabolite of triamterene found was the sulfate conjugate. The area under the curve of this metabolite amounted to 6.672±2.120 and 11.941±5.005 µg/ml × h after the of 150 mg and 300 mg triamterene doses, respectively. The urinary excretion of the metabolite varied between 25.0±4.0% and 17.5±3.5% of the dose after either dose. In healthy subjects an effect on sodium excretion was observed after a dose of 150 mg, whereas the potassium-retaining effect was observed only after the dose of 300 mg.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andrasch, H., Fink, T., Schmid, E.: Über die Harnausscheidung des Antikaliuretikums Triamteren und seines phenolischen Metaboliten 2,4,7-Triamino-6-p-hydroxy-phenylpteridin bei Lebergesunden und Kranken mit Leberzirrhose. Z. Gastroenterol.9, 240–245 (1971)
Baba, W. J., Tudhope, G. R., Wilson, G. M.: Triamterene, a new diuretic drug. I. Studies in normal men and in adrenalectomized rats. Br. Med. J.,1962/II, 756–760
Badinand, A., Rondelet, J., Vallon, J. J., Chappuis, O.: Étude de l'élimination urinaire et du passage sanguin du Triamtérène. J. Med. (Lyon)1047, 19–26 (1964)
Dayton, P. G., Ansley, J., Pruitt, A. W., Winkel, J., Rudman, D.: Impairment of p-hydroxylation of triamterene in patients with cirrhosis. Pharmacologist18, 153 (1976)
Dettli, L., Spring, P.: Pharmakologisch-klinische Prüfung neuer Diuretika. Arzneim. Forsch.15, 1162–1168 (1965)
Grebian, B., Geißler, H. E., Mutschler, E.: Über die Bestimmung von Triamteren, Hydroxytriamteren und Hydroxy-triamteren-schwefelsäureester in biologischem Material durch direkte Auswertung von Dünnschichtchromatogrammen. Arzneim.-Forsch. (Drug Res.)26, 2125–2127 (1976)
Greeff, K., Köhler, E.: Tierexperimentelle Untersuchungen über den Einfluß von Triamteren und Amilord auf Herz, Kreislauf und Toxizität des Digoxins. Arzneim. Forsch. (Drug Res.)25, 1766–1769 (1975)
Gundert-Remy, U.: Biliary and renal elimination of 14-C-triamterene in the rat. Naunyn-Schmiedebergs Arch. Pharmacol.297, Suppl. II R 9 (1977)
Lassen, J. B., Nielsen, O. E., Investigation into diuretic effect and elimination of triamterene. Acta Pharmacol. Toxicol.20, 309–316 (1963)
Lehmann, K.: Isolierung und Identifizierung von Stoffwechselprodukten des Triamteren. Arzneim. Forsch. (Drug Res.)15, 812–816 (1965)
Pruitt, A. W., Winkel, J. S., Dayton, P. G.: Variations in the fate of triamteren. Clin. Pharmacol. Ther.21, 610–619 (1977)
Seller, R. H., Greco, J., Banach, St., Seth, R.: Increasing the inotropic effect and toxic dose of digitalis by the administration of antikaliuretic drugs — further evidence for a cardiac effect of diuretic agents. Am. Heart J.90, 56–67 (1975)
Siegel, S.: Non-parametric statistics, pp. 75–83. New York: McGraw-Hill 1956
Heh, B. K., Francis, J. S., Gosselin, A. J., Relias, R. A.: Antiarrhythmic activity of four pteridine compunds in ouabain intoxication. Clin. Pharmacol. Ther.17, 141–145 (1975)
Weber, D. J.: Intravenous triamterene in the treatment of acute digitalis intoxication. Clin. Pharmacol. Ther.13, 868–874 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gundert-Remy, U., von Kenne, D., Weber, E. et al. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man. Eur J Clin Pharmacol 16, 39–44 (1979). https://doi.org/10.1007/BF00644964
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00644964